MCS 110

Drug Profile

MCS 110

Alternative Names: MCS110

Latest Information Update: 25 Jul 2016

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Giant cell tumour of tendon sheath; Pigmented villonodular synovitis
  • Phase I/II Solid tumours
  • Discontinued Bone metastases; Prostate cancer

Most Recent Events

  • 17 Jul 2016 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in Finland and Spain (Parenteral) (NCT02807844; EudraCT2016-000210-29)
  • 22 Jan 2016 Phase-II clinical trials in Breast cancer (Combination therapy, Late-stage disease) in France and Hong Kong (IV)
  • 14 Sep 2015 Phase-II development for Pigmented villonodular synovitis and Giant cell tumour of tendon sheath is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top